{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-276103","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-06-18T21:16:09+00:00","discovered_at":"2026-06-18T21:18:00.294000+00:00","generated_at":"2026-06-18T21:19:50.910992+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jaguar Health amends royalty agreements to $750k minimum, extends Streeterville debt, exchanges preferred for common","bullets":["Royalty amendments: Uptown and Streeterville minimum monthly payment increased to $750k, effective Oct 1, 2026.","Streeterville royalty payment start extended from July 1 to Oct 1, 2026; $6.22M note maturity also extended to Oct 1, 2026.","Exchanged 10.88 shares of Series Q Preferred for 110,249 common shares (three deals June 9, 17, 18).","Aggregate common stock issuance exceeded 5% of outstanding; shares free-trading without legend under Section 3(a)(9)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-276103","json":"https://secwatch.observer/filing/0001193125-26-276103.json","markdown":"https://secwatch.observer/filing/0001193125-26-276103.md","text":"https://secwatch.observer/filing/0001193125-26-276103.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/d111863d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T21:19:50.910992+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40838bdad65367b0eff6ca1a0238943f42789c28","claim":"Jaguar Health, Inc. amended debt of original principal amount of $12 million with Uptown Capital, LLC.","evidence_excerpt":"On June 17, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), pursuant to which Section 2.2 of the Uptown 2020 Royalty Interest was deleted and replaced in its entirety such that, beginning on October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Uptown is entitled to for such month pursuant to Section 2.1 of the Uptown 2020 Royalty Interest.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"original principal amount of $12 million"},{"label":"Counterparty","value":"Uptown Capital, LLC"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"658b9fe984ea59d30fbf8e2288ffb1b643bdbf21","claim":"Jaguar Health, Inc. amended debt of original principal amount of $12 million with Streeterville Capital, LLC.","evidence_excerpt":"On June 17, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million dated August 24, 2022, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which Section 2.2 of the Streeterville 2022 Royalty Interest was deleted and replaced in its entirety such that initiation of monthly payments shall be extended from July 1, 2026 to October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Streeterville is entitled to for such month pursuant to Section 2.1 of the Streeterville 2022 Royalty Interest.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Principal","value":"original principal amount of $12 million"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"910bb50f889d486839e8971840be35e2e52e97c2","claim":"Jaguar Health, Inc. amended loan of original principal amount of $6,220,812.50 with Streeterville Capital, LLC maturing October 1, 2026.","evidence_excerpt":"On June 17, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 4”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date. Pursuant to the 2021 Note Amendment No. 4, the maturity date of the 2021 Note is extended from July 1, 2026 to October 1, 2026.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"original principal amount of $6,220,812.50"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Maturity","value":"October 1, 2026"},{"label":"Event","value":"amendment"}],"fact_type":"debt_financing"},{"claim_id":"07d8573b1b17a356df01f05e1bdd2d046e1e45e5","claim":"Jaguar Health, Inc. amended 2021 Note Amendment No. 4 with Streeterville Capital, LLC (as lender, together with Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. as borrower) (effective 2026-06-17).","evidence_excerpt":"On June 17, 2026, the Company and Napo Pharmaceuticals, Inc., the Company’s wholly-owned subsidiary (“Napo” and together with the Company, the “Borrower”), entered into an amendment (the “2021 Note Amendment No. 4”) with Streeterville to the secured promissory note in the original principal amount of $6,220,812.50 (as amended, the “2021 Note”) issued by Borrower to Streeterville on January 19, 2021 pursuant to that certain Note Purchase Agreement among the same parties dated as of the even date.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Streeterville Capital, LLC (as lender, together with Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. as borrower)"},{"label":"Effective","value":"2026-06-17"}],"fact_type":"material_agreement"},{"claim_id":"0ff991a1de964cf966168637a31477c93ebe0c49","claim":"Jaguar Health, Inc. entered into Second Exchange Agreement with Streeterville Capital, LLC (\"Streeterville\") (effective 2026-06-17).","evidence_excerpt":"On June 17, 2026, the Company entered into another privately negotiated exchange agreement with Streeterville (the “Second Exchange Agreement”), pursuant to which the Company issued 36,796 shares (the “Second Exchange Shares”) of Common Stock to Streeterville in exchange for an aggregate of 3.4 outstanding shares of Series Q Preferred Stock held by Streeterville (the “Second Exchanged Preferred Shares”), which when combined with the First Exchange Shares resulted in the aggregate issuance by the Company of more than 5% of the Company’s issued and outstanding shares of Common Stock, as last reported in the Company’s Quarterly Report on Form 10-Q filed on May 20, 2026.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Streeterville Capital, LLC (\"Streeterville\")"},{"label":"Effective","value":"2026-06-17"}],"fact_type":"material_agreement"},{"claim_id":"618f5b2522be7c7cf208068fe1b56b1ea5aa8e8d","claim":"Jaguar Health, Inc. entered into First Exchange Agreement with Streeterville Capital, LLC (\"Streeterville\") (effective 2026-06-09).","evidence_excerpt":"On June 9, 2026, the Company entered into a privately negotiated exchange agreement with Streeterville (the “First Exchange Agreement”), pursuant to which the Company issued 34,798 shares (the “First Exchange Shares”) of the Company’s common stock, par value $0.0001 (the “Common Stock”), to Streeterville in exchange for an aggregate of 3.8 outstanding shares of Series Q Preferred Stock held by Streeterville (the “First Exchanged Preferred Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Streeterville Capital, LLC (\"Streeterville\")"},{"label":"Effective","value":"2026-06-09"}],"fact_type":"material_agreement"},{"claim_id":"757605ec356bbffab40ef8048bcb43a974276417","claim":"Jaguar Health, Inc. amended Streeterville 2022 Royalty Interest Global Amendment No. 5 with Streeterville Capital, LLC (\"Streeterville\") (effective 2026-06-17).","evidence_excerpt":"On June 17, 2026, the Company also entered into an amendment (the “Streeterville 2022 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million dated August 24, 2022, as amended (the “Streeterville 2022 Royalty Interest”) with Streeterville Capital, LLC (“Streeterville”), pursuant to which Section 2.2 of the Streeterville 2022 Royalty Interest was deleted and replaced in its entirety such that initiation of monthly payments shall be extended from July 1, 2026 to October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Streeterville is entitled to for such month pursuant to Section 2.1 of the Streeterville 2022 Royalty Interest.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Streeterville Capital, LLC (\"Streeterville\")"},{"label":"Effective","value":"2026-06-17"}],"fact_type":"material_agreement"},{"claim_id":"8cdbda7333e1b8102528319b0f3b6d5621c8b720","claim":"Jaguar Health, Inc. amended Uptown 2020 Royalty Interest Global Amendment No. 5 with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; \"Uptown\") (effective 2026-06-17).","evidence_excerpt":"On June 17, 2026, Jaguar Health, Inc. (the “Company”) entered into an amendment (the “Uptown 2020 Royalty Interest Global Amendment No. 5”) to the royalty interest in the original principal amount of $12 million, as amended (the “Uptown 2020 Royalty Interest”) with Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; “Uptown”), pursuant to which Section 2.2 of the Uptown 2020 Royalty Interest was deleted and replaced in its entirety such that, beginning on October 1, 2026, the monthly Royalty Payment shall be the greater of (a) $750,000.00, and (b) the actual Royalty Payment amount Uptown is entitled to for such month pursuant to Section 2.1 of the Uptown 2020 Royalty Interest.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526276103/0001193125-26-276103-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Counterparty","value":"Uptown Capital, LLC (f/k/a Irving Park Capital, LLC; \"Uptown\")"},{"label":"Effective","value":"2026-06-17"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}